U.S. Paper and Forestry Products Stock News

In its most recent quarter, Pacific Biosciences of California reported strong uptake of its Revio and Vega sequencing platforms and launched the SPRQ-Nx chemistry, which lowers long-read sequencing costs and broadens clinical research applications through its PureTarget portfolio. An important angle is that many recent system placements came from first-time customers, meaning the company is expanding its installed base rather than relying solely on existing users. We’ll now examine how the...

Context for Rumble’s recent trading Rumble (RUM) has drawn fresh attention after recent share price moves, with the stock down over the past month and past 3 months, while still positive year to date. This has prompted investors to reassess its video platform and cloud ambitions. See our latest analysis for Rumble. Rumble’s latest share price of US$6.61 sits slightly above where it started the year, with a 3.8% year to date share price return. However, its 1 year total shareholder return of a...

In December 2025, Weibo Corporation announced a share repurchase program authorizing the buyback of up to US$200 million of its American depositary shares, to be funded from existing cash and running through December 31, 2026. This buyback authorization highlights Weibo’s use of its balance sheet to return capital to shareholders, which can influence perceptions of capital allocation discipline and management confidence in the business. We’ll now examine how Weibo’s US$200 million share...

At CES 2026, AMD introduced a broad slate of AI hardware spanning Helios rack-scale data center systems, next-generation Instinct accelerators, Ryzen AI PC platforms, and new Ryzen AI Embedded chips for automotive, industrial, and edge use cases. Autolink’s newly announced collaboration to build a Deep Fusion vehicle architecture on AMD Versal AI Edge Gen 2 SoCs underscores AMD’s push to embed its AI technology directly into future intelligent vehicles and physical AI systems. Next, we’ll...

Earlier this week, FormFactor announced that CEO Mike Slessor sold 39,606 shares, while continuing to hold 485,995 shares in the company, against a backdrop of strong sector interest in its semiconductor test and measurement technologies. The absence of insider share purchases over the past year, alongside multiple insider sales, offers investors an additional lens on internal sentiment and capital allocation decisions. We’ll now examine how the CEO’s recent share sale, alongside sector-wide...

Cousins Properties (CUZ) is drawing attention after recent price moves, with the stock closing at US$25.83 as investors weigh its role as a Sun Belt focused office REIT and assess its current valuation. See our latest analysis for Cousins Properties. The recent pullback, including a 2.57% 1 day share price decline, comes after a 6.56% 30 day share price return. The 1 year total shareholder return of an 8.69% decline contrasts with a 17.94% gain over three years, suggesting longer term...

Recent attention on Napco Security Technologies (NSSC) centers on its 10.2% annual revenue growth and 12.8% annual net income growth, along with solid free cash flow and higher returns on capital that highlight management’s capital allocation. See our latest analysis for Napco Security Technologies. Even with recent choppy trading, including a 4.2% decline in the 90 day share price return and a 1 year total shareholder return of 19%, momentum still looks more supportive over the longer term...

In recent days, Teladoc Health has continued to face pressure as competition intensifies, BetterHelp loses paying members, and the company remains unprofitable despite cost-control efforts and AI investments. This combination of weakening growth in a core mental health business, rising rivalry from large tech and insurance players, and cautious analyst sentiment has reinforced investor concerns about Teladoc’s longer-term business trajectory. We’ll now examine how BetterHelp’s member losses...

Zymeworks Inc. recently reported positive Phase 3 HERIZON-GEA-01 results showing that Ziihera (zanidatamab-hrii) plus chemotherapy, with or without Tevimbra (tislelizumab), improved progression-free and overall survival versus trastuzumab plus chemotherapy in adults with HER2-positive metastatic gastroesophageal adenocarcinoma, with data presented as a late-breaking oral session at the 2026 ASCO-GI symposium. The trial’s efficacy and manageable safety profile could support Ziihera’s use as a...

Why CarGurus (CARG) is on investors’ radar today CarGurus (CARG) is drawing attention after recent share price moves, with the stock closing at US$37.97 and posting mixed short term returns alongside stronger gains over the past 3 months and year. See our latest analysis for CarGurus. While the 1 day and 7 day share price returns have been slightly negative, the 30 day and 90 day share price returns of 7.23% and 11.71% suggest momentum has been building, alongside a 3 year total shareholder...

Arrowhead Pharmaceuticals (ARWR) is in focus after early clinical data for its obesity candidates ARO-INHBE and ARO-ALK7, along with new approvals for REDEMPLO in Canada and China, highlighted progress across its RNAi pipeline. See our latest analysis for Arrowhead Pharmaceuticals. Despite the positive obesity data and fresh REDEMPLO approvals, Arrowhead’s 1-day share price return of a 7.23% decline and 30-day share price return of a 4.24% decline contrast with a sharp 90-day share price...

Aflac recently disclosed that a sophisticated cyberattack affected about 22.65 million individuals and has since partnered with CyEx to provide its Medical Shield medical fraud protection service, offering monitoring that extends beyond standard credit checks. This move underscores how cybersecurity and post-breach care are becoming core parts of the value proposition for major supplemental health and life insurers like Aflac. Now we’ll explore how Aflac’s cyber incident response, including...

BridgeBio Pharma recently announced an investor webinar held on January 9, 2026, to discuss achondroplasia and Phase 3 PROPEL 3 data for infigratinib, alongside upcoming presentations at the J.P. Morgan Healthcare Conference. This focus on late-stage clinical progress comes as analysts highlight BridgeBio’s growing commercial footprint with Attruby and its broader rare disease pipeline, while investors scrutinize insider selling activity. We’ll now examine how the insider selling and...

Why Sionna Therapeutics (SION) is on investors’ radar today Sionna Therapeutics (SION) has attracted fresh attention after a recent 16.1% one day move, as investors reassess this clinical stage cystic fibrosis developer. See our latest analysis for Sionna Therapeutics. That 16.1% one day share price return comes on top of a 46.9% 90 day share price return and a 10.2% year to date gain, suggesting momentum has been building rather than fading, with the stock now at $43.21. If you are looking...

Genesis Energy (NYSE:GEL) has drawn attention after its recent trading performance, with a 5% decline over the past month and a 1% slip over the past three months prompting closer scrutiny of its fundamentals. See our latest analysis for Genesis Energy. While the recent 1-month share price return of 4.75% and 3-month share price return of 1.04% are both negative, Genesis Energy’s 1-year total shareholder return of 54.33% and 5-year total shareholder return of about 3x suggest longer term...

Aurora Innovation recently expanded its autonomous trucking footprint through partnerships involving Amazon Web Services, German supplier Aumovio, Nvidia, Continental, and logistics firm Detmar, building on its status as the first company to commercially operate driverless heavy-duty trucks on U.S. public roads. A particularly interesting angle is Aurora’s move into autonomous frac sand hauling in the Permian Basin, which shows how its driverless technology is being customized for complex,...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

If you are wondering whether Vertiv Holdings Co at US$171.54 is still priced reasonably or already stretched, you are not alone. The stock has been volatile recently, with a 5.9% gain over the last 7 days, a 7.6% decline over 30 days, a 2.3% decline year to date, and a 32.9% return over the past year, while its 3 year and 5 year returns are described as very large. These swings have kept Vertiv on many investors' watchlists, as rapid multi year moves often prompt questions about what is...

UBS recently initiated research coverage on Oruka Therapeutics with a positive rating and a US$50 price target, spotlighting the clinical‑stage biotech’s peptide‑based oncology and immune‑mediated disease programs. This coverage effectively elevates Oruka’s profile among institutional investors by framing its pipeline as part of a broader recovery narrative in the biotech sector. Next, we’ll examine how UBS’s new coverage and its emphasis on Oruka’s peptide‑based oncology platform shape the...

The Council of Fashion Designers of America and Ralph Lauren Corporation recently launched two grant programs to support modernizing, expanding, and training within New York City’s Garment District and apparel manufacturers across the U.S. By backing these manufacturing funds, Ralph Lauren is reinforcing its role in shaping the American fashion supply chain and production capabilities alongside its premium brand focus. We’ll now examine how Ralph Lauren’s support for U.S. fashion...

LandBridge (LB) is in focus after agreeing to acquire 1918 Ranch. The deal is expected to add about $20 million in EBITDA for fiscal 2026, alongside fresh debt and equity financing moves. See our latest analysis for LandBridge. Those moves come after a tough stretch for the stock, with a 30-day share price return decline of 23.24% and a 1-year total shareholder return decline of 38.19%, suggesting momentum has been fading despite recent capital raising and acquisition news. If this kind of...

ZipRecruiter, Inc.'s (NYSE:ZIP) stock price has dropped 10.0% in the previous week, but insiders who sold US$887k in...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

A Montana federal judge has allowed a high profile class-action lawsuit over toxic PFAS chemicals in firefighter gear to proceed against Chemours (CC) and other manufacturers, keeping potential liability and reputational questions in focus for shareholders. See our latest analysis for Chemours. Chemours shares trade at US$13.07, with a 7 day share price return of 10.86% and a 30 day gain of 7.13%. However, a 1 year total shareholder return decline of 24.19% and a 3 year total shareholder...